Raras
Buscar doenças, sintomas, genes...
Miopatia metabólica
ORPHA:98486DOENÇA RARA

Um grupo de doenças raras e hereditárias, causadas pela falta de enzimas que participam de processos do metabolismo que afetam os músculos. Essas doenças se caracterizam por um mau funcionamento dos músculos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um grupo de doenças raras e hereditárias, causadas pela falta de enzimas que participam de processos do metabolismo que afetam os músculos. Essas doenças se caracterizam por um mau funcionamento dos músculos.

Publicações científicas
493 artigos
Último publicado: 2026 Apr 10
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
17 sintomas
😀
Face
2 sintomas
🩸
Sangue
2 sintomas
🦴
Ossos e articulações
1 sintomas
🧠
Neurológico
1 sintomas
👁️
Olhos
1 sintomas

+ 22 sintomas em outras categorias

Características mais comuns

Fibras musculares vermelhas rasgadas
Aumento da concentração circulante de lactato
Atividade diminuída do complexo II mitocondrial
Intolerância ao exercício
Concentração elevada de creatina quinase circulante
Atividade diminuída do complexo IV mitocondrial
47sintomas
Sem dados (47)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 47 características clínicas mais associadas, ordenadas por frequência.

Fibras musculares vermelhas rasgadasRagged-red muscle fibers
Aumento da concentração circulante de lactatoIncreased circulating lactate concentration
Atividade diminuída do complexo II mitocondrialDecreased activity of mitochondrial complex II
Intolerância ao exercícioExercise intolerance
Concentração elevada de creatina quinase circulanteElevated circulating creatine kinase concentration

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico493PubMed
Últimos 10 anos200publicações
Pico202524 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição.

ISCUIron-sulfur cluster assembly enzyme ISCUDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial scaffold protein, of the core iron-sulfur cluster (ISC) assembly complex, that provides the structural architecture on which the [2Fe-2S] clusters are assembled (PubMed:34824239). The core iron-sulfur cluster (ISC) assembly complex is involved in the de novo synthesis of a [2Fe-2S] cluster, the first step of the mitochondrial iron-sulfur protein biogenesis. This process is initiated by the cysteine desulfurase complex (NFS1:LYRM4:NDUFAB1) that produces persulfide which is delivered

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Maturation of replicase proteins
MECANISMO DE DOENÇA

Myopathy with exercise intolerance Swedish type

Autosomal recessive metabolic disease characterized by lifelong severe exercise intolerance, in which minor exertion causes fatigue of active muscles, shortness of breath, and cardiac palpitations in association with lactic acidosis. The biochemical phenotype is characterized by a deficiency in mitochondrial iron-sulfur proteins and impaired muscle oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
227.3 TPM
Artéria tibial
216.8 TPM
Aorta
216.1 TPM
Cervix Ectocervix
200.3 TPM
Artéria coronária
194.7 TPM
OUTRAS DOENÇAS (1)
hereditary myopathy with lactic acidosis due to ISCU deficiency
HGNC:29882UniProt:Q9H1K1
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
SLC16A1Monocarboxylate transporter 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Bidirectional proton-coupled monocarboxylate transporter (PubMed:12946269, PubMed:32946811, PubMed:33333023). Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, acetate and the ketone bodies acetoacetate and beta-hydroxybutyrate, and thus contributes to the maintenance of intracellular pH (PubMed:12946269, PubMed:33333023). The transport direction is determined by the proton motive force and the concentration gradient of the substrate mon

LOCALIZAÇÃO

Cell membraneBasolateral cell membraneApical cell membrane

VIAS BIOLÓGICAS (3)
Aspirin ADMEProton-coupled monocarboxylate transportBasigin interactions
MECANISMO DE DOENÇA

Symptomatic deficiency in lactate transport

Deficiency of lactate transporter may result in an acidic intracellular environment created by muscle activity with consequent degeneration of muscle and release of myoglobin and creatine kinase. This defect might compromise extreme performance in otherwise healthy individuals.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
63.2 TPM
Linfócitos
42.4 TPM
Testículo
38.0 TPM
Cólon sigmoide
36.8 TPM
Cólon transverso
32.2 TPM
OUTRAS DOENÇAS (3)
ketoacidosis due to monocarboxylate transporter-1 deficiencymetabolic myopathy due to lactate transporter defectexercise-induced hyperinsulinism
HGNC:10922UniProt:P53985

Variantes genéticas (ClinVar)

368 variantes patogênicas registradas no ClinVar.

🧬 SLC16A1: NM_003051.4(SLC16A1):c.1153C>T (p.Gln385Ter) ()
🧬 SLC16A1: NM_003051.4(SLC16A1):c.1207C>T (p.Leu403Phe) ()
🧬 SLC16A1: NM_003051.4(SLC16A1):c.74G>T (p.Gly25Val) ()
🧬 SLC16A1: NM_003051.4(SLC16A1):c.97del (p.Ser33fs) ()
🧬 SLC16A1: NM_003051.4(SLC16A1):c.764T>G (p.Leu255Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 9 variantes classificadas pelo ClinVar.

2
2
5
Patogênica (22.2%)
VUS (22.2%)
Benigna (55.6%)
VARIANTES MAIS SIGNIFICATIVAS
SLC16A1: NM_003051.4(SLC16A1):c.747_750del (p.Asn250fs) [Pathogenic/Likely pathogenic]
SLC16A1: NM_003051.4(SLC16A1):c.1414G>A (p.Gly472Arg) [Conflicting classifications of pathogenicity]
SLC16A1: NM_003051.4(SLC16A1):c.98C>G (p.Ser33Cys) [Uncertain significance]
SLC16A1: NM_003051.4(SLC16A1):c.610A>G (p.Lys204Glu) [Uncertain significance]
SLC16A1: NM_003051.4(SLC16A1):c.362-58TATT[8] [Benign/Likely benign]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Miopatia metabólica

Centros de Referência SUS

21 centros habilitados pelo SUS para Miopatia metabólica

Centros para Miopatia metabólica

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

7 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
213 papers (10 anos)
#1

Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.

Neurology. Clinical practice2026 Feb

Statins are widely prescribed lipid-lowering agents, but their safety and tolerability in patients with underlying genetic myopathies remain uncertain. We aimed to study statin safety and tolerability in genetic myopathies using a large retrospective cohort. We conducted a retrospective study in patients with myotonic dystrophy type 1 (DM1) and type 2 (DM2), facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and metabolic or mitochondrial myopathies who were exposed to statins. We included 135 patients (36 with DM1, 46 with DM2, 22 with FSHD, 6 with LGMD, 17 with mitochondrial myopathy, 6 with glycogenosis, and 2 with disorders of fatty acid oxidation or carnitine transport). A total of 44 patients discontinued statins, most often for statin-associated muscle symptoms (SAMS; n = 20). SAMS occurred in 36 of 135 patients (26.67%; 8 with DM1, 10 with DM2, 7 with FSHD, 3 with LGMD, 4 with mitochondrial myopathy, and 4 with metabolic myopathy). Myalgias were the most frequent SAMS (n = 29). Rhabdomyolysis occurred in 4 patients (1 with mitochondrial myopathy and 3 with McArdle disease). Statins unmasked myopathy in 6 of 36 patients. No patient developed immune-mediated necrotizing myopathy. SAMS are generally mild and occur at a frequency similar to the general population in common genetic myopathies, except increased rhabdomyolysis in mitochondrial myopathies and McArdle disease. Statins are generally safe, though not well tolerated, and could be used when closely monitored in several genetic myopathies. In mitochondrial and metabolic myopathies, their use should be approached with caution because of the potential risk of rhabdomyolysis.

#2

Myopathy and ataxia related to impaired mitochondrial function in mevalonate kinase deficiency.

Orphanet journal of rare diseases2026 Feb 12

Mevalonate kinase deficiency (MKD) is a rare genetic disorder, resulting in the lack of the mevalonate kinase enzyme (MVK), which is involved in the biosynthesis of cholesterol, non-sterol isoprenoids, and coenzyme Q10 (CoQ10). The more severe phenotype of MKD is known as mevalonic aciduria (MA), typically presenting as a multisystemic inflammatory syndrome with possible neurological manifestations, such as developmental delay, cerebellar ataxia, and retinopathy. Myopathy or isolated hyperCKemia have been rarely reported in association with MA. However, a few studies evidenced mitochondrial dysfunction in MVK deficient cells. To point out the connection between MKD, myopathy, and mitochondrial dysfunction, describing two cases of MA. We report on two unrelated patients with myopathy and ataxia, providing clinical, histological, biochemical, and genetic data of MKD. Both patients were referred to the Neurology Department in the first year of life, due to muscle weakness, gait disturbances, and increased levels of CK value. Muscle biopsy was performed, showing some mitochondrial alterations and mild lipid storage. Interestingly, biochemical studies on muscle homogenate revealed a reduction of mitochondrial respiratory chain activities and CoQ10 levels. Genetic analysis confirmed the MKD diagnosis, evidencing a homozygous MVK gene mutation in the first case, and compound heterozygous mutations in the second one. This report describes two MKD cases with clinical and morphological evidence of muscle involvement in the spectrum of MA related to mitochondrial dysfunction.

#3

EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia.

European journal of neurology2026 Feb

Recent epidemiological studies on the general population reveal that up to 1.3% have oligo/asymptomatic hyperCKemia. This guideline aims to provide updated, evidence-based recommendations on investigating persons older than 18 years. The guideline followed EAN standard operating procedures and was developed according to the GRADE methodology. Fourteen neuromuscular experts from the EAN neuromuscular group were joined by a methodologist and a patient representative. There are two types of recommendations: evidence-based recommendations, based on published studies, and consensus statements if the quality of evidence is poor. We recommend that: (1) Persistent oligo/asymptomatic hyperCKemia with a CK > 1.5 ULN be investigated (Consensus statement); (2) Neurogenic and non-neuromuscular causes of hyperCKemia be excluded (Expert opinion); (3) A Dried Blood Spot (DBS) be done (Strong recommendation); (4) A NCS/EMG to identify whether there is a myopathy or neuropathy be performed (Weak recommendation); (5) A resting lactate and fasting acyl-carnitine assays, if a metabolic myopathy is suspected, be done (Consensus statement); (6) A skeletal muscle MRI be performed to guide/interpret genetic testing (Strong recommendation); (7) NGS is recommended over sequential gene testing (Consensus statement); (8) NGS is recommended over muscle biopsy (Strong recommendation); (9) A muscle biopsy may be offered, if genetic testing is uninformative and one or more applies: a genetic variant of unknown significance (VUS), suspected metabolic myopathy, suspected inflammatory myopathy, abnormal muscle MRI, a CK ≥ 3 ULN, a family history of muscle disease or age, less than 25 years (Expert opinion). An evidence-based guideline is suggested for when and how to investigate adults with oligo/asymptomatic hyperCKemia.

#4

Loss of adenylosuccinate synthetase 1 in mice recapitulates features of ADSS1 myopathy.

Human molecular genetics2026 Feb 08

ADSS1 myopathy is an ultrarare congenital myopathy characterized by progressive cardiac and skeletal muscle degeneration with childhood to adolescent onset. This autosomal recessive disease is caused by mutations in the ADSS1 gene, encoding the enzyme adenylosuccinate synthetase (AdSS1). AdSS1 plays a critical role in the adenine nucleotide cycle, which is important for energy metabolism in muscle cells. Enzymatic defects, engendered by loss-of-function mutations in ADSS1, lead to a bottleneck in the adenine nucleotide cycle, causing metabolic dysfunction that ultimately results in progressive muscle weakness, mobility impairment, and respiratory and cardiac dysfunction, often requiring the use of a ventilator. Despite its debilitating nature, there are currently no cures or targeted treatments available, and little research into possible therapeutic strategies has been done. With a limited patient profile encompassing fewer than 200 known patients worldwide, establishing a mouse model for ADSS1 myopathy is critical to understanding its pathogenesis and for developing future therapies. Here, we present and characterize the first mouse model of ADSS1 myopathy-a constitutive Adss1 knockout model-by (1) defining its natural history, (2) exploring its metabolic pathomechanisms, and (3) characterizing its histopathological features. We find that Adss1KO/KO mice have subtle motor deficits and present with histopathological features consistent with patient phenotypes. Overall, we show that despite a relatively mild phenotype, this novel mouse model has quantifiable pathological features that can be used to develop therapies for, and further probe pathophysiology of, ADSS1 myopathy.

#5

The Impact of Muscle Fatigue on McArdle Disease: A Case Report.

Cureus2026 Feb

McArdle disease (McA) is a rare metabolic disorder of autosomal recessive inheritance caused by pathogenic variants in the PYGM gene, which lead to a deficiency of the myophosphorylase enzyme. This enzymatic defect impairs muscle glycogenolysis, typically resulting in exercise intolerance, premature fatigue, and exertional cramps triggered by anaerobic or high-intensity physical activity starting in childhood or adolescence. However, the diagnosis is frequently delayed due to the heterogeneous and non-specific presentation of these symptoms. The authors report a case of a 61-year-old woman with a lifelong history of exercise intolerance and disproportionate muscle fatigue that restricted her physical activity since her youth. She presented with persistent, idiopathic elevations of creatine kinase (CK) over several years. The patient had no history of myoglobinuria and showed preserved renal function and no evidence of acute rhabdomyolysis, despite marked hyperCKemia. Cardiac involvement was also excluded. After excluding more common secondary causes of hyperCKemia, such as statin-induced myopathy and inflammatory conditions, the persistence of marked hyperCKemia and specific exercise-induced symptoms suggested a metabolic myopathy, such as McArdle disease. Molecular analysis was performed, identifying the homozygous pathogenic variant c.280C>T (p.Arg94Trp) in the PYGM gene and confirming the diagnosis of McArdle disease.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC86 artigos no totalmostrando 196

2026

The Impact of Muscle Fatigue on McArdle Disease: A Case Report.

Cureus
2026

Comparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data.

Journal of comparative effectiveness research
2026

Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.

Neurology. Clinical practice
2026

Water Extract of Polygonati Rhizoma Ameliorates Obesity-Related Skeletal Muscle Atrophy in Mice and C2C12 Myotubes.

Nutrients
2026

Myopathy and ataxia related to impaired mitochondrial function in mevalonate kinase deficiency.

Orphanet journal of rare diseases
2026

A Pediatric Case of Stiff-Person Syndrome: Presentation and Comparative Analysis.

Journal of orthopaedic case reports
2026

Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease.

Neuromuscular disorders : NMD
2026

Molecular Mechanisms and Therapeutic Potential of DJ-1 in Skeletal Muscle Homeostasis and Disease.

Comprehensive Physiology
2026

EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia.

European journal of neurology
2025

Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review.

Frontiers in immunology
2025

Etoposide-Associated Severe Rhabdomyolysis in a Patient with Diffuse Large B-Cell Lymphoma: A case report and review of the literature.

Sultan Qaboos University medical journal
2026

Influence of a 12 week at-home resistance exercise program on 13C-glucose metabolism in patients with metabolic myopathies.

Molecular genetics and metabolism
2025

Diagnostic Value of Muscle Biopsy for the Evaluation of Adult Myopathy in Daily Clinical Practice.

Diagnostics (Basel, Switzerland)
2025

Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD): Clinical Features, Diagnostic Challenges, and the Role of Oxidative Stress in Pathophysiology.

Antioxidants (Basel, Switzerland)
2025

Multiomics Integration Reveals a Metabolic Myopathy in Cardiometabolic HFpEF.

bioRxiv : the preprint server for biology
2026

Lactate-induced mitochondrial magnesium uptake and its metabolic implications in the McArdle disease model.

Biochimica et biophysica acta. Molecular basis of disease
2025

Late-onset Pompe's disease in pediatrics: results from an Italian national survey on 38 patients and proposal of a targeted diagnostic algorithm.

Orphanet journal of rare diseases
2026

Loss of adenylosuccinate synthetase 1 in mice recapitulates features of ADSS1 myopathy.

Human molecular genetics
2025

When Fatigue Hides A Metabolic Myopathy: A Case Report of Mcardle Disease with Molecular Diagnosis.

European journal of case reports in internal medicine
2025

National diagnostic gaps for TK2 Deficiency in Italy: insights from the AIM Multicenter Survey.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2025

Causes of Death and Comorbidities in Adult Patients With Late-Onset Pompe Disease: A French Pompe Registry Retrospective Study.

European journal of neurology
2025

A disease that is difficult to predict: regional distribution and phenotypic, histopathological and genetic findings in McArdle disease.

Journal of pediatric endocrinology & metabolism : JPEM
2025

A novel XPNPEP3 gene variant manifesting as rhabdomyolysis and exercise intolerance.

Journal of neuromuscular diseases
2026

Marked Improvements in Airway Abnormalities and Multifaceted Outcomes After 2 Years Switching to Avalglucosidase Alfa: Evaluation of A 19-Year-Old Male Diagnosed With Late-Onset Pompe Disease.

American journal of medical genetics. Part A
2025

McLeod syndrome mimicking mitochondrial myopathy due to a novel in-frame duplication in the XK gene.

Neuromuscular disorders : NMD
2025

Searching for Clues in the Diagnosis of McArdle Disease.

Cureus
2025

A Rare Case of Myasthenia Gravis With Underlying Aldolase A Deficiency: Diagnostic and Therapeutic Challenges.

Cureus
2025

Impact of individualized and supervised strength training on muscle physiology, metabolic control and quality of life in metabolic myopathies.

Scientific reports
2025

Limb-girdle muscular dystrophy type 2Y with cardiac involvement in a 23-year-old woman: a case report.

European heart journal. Case reports
2025

Severe rhabdomyolysis in an infant due to fatty acid oxidation disorder: a case report.

Journal of medical case reports
2025

A Case of Adult-Onset VLCAD Deficiency.

Journal of clinical neuromuscular disease
2025

McArdle Disease: Insights Into a Rare Metabolic Myopathy in a Young Boy With Recurrent Exercise-Induced Muscle Weakness.

Cureus
2025

Exploring the use of the National Institutes of Health Toolbox Cognition Battery with children and adolescents with Pompe disease: Preliminary findings.

Molecular genetics and metabolism
2025

Camptocormia as a feature of Mc Ardle's disease: A case report.

Molecular genetics and metabolism reports
2025

Glycogen storage disease type V: delayed diagnosis of a cause of exercise intolerance in a patient with hereditary haemorrhagic telangiectasia.

BMJ case reports
2025

2-[18F] FDG PET/CT in Rapid Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency: A Case Report.

JIMD reports
2024

Health-Related Quality of Life and Fatigue in Children with Pompe Disease.

Journal of pediatrics. Clinical practice
2024

Relevance of muscle biopsies in the neonatal and early infantile period: a 52 years retrospective study in the gene-sequencing era.

Acta neuropathologica communications
2025

Phenotypic variability in congenital myasthenic syndrome with GFPT1 mutation.

Acta neurologica Belgica
2024

The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).

Orphanet journal of rare diseases
2024

Effectiveness of Respiratory Muscle Training in Pompe Disease: A Systematic Review and Meta-Analysis.

Children (Basel, Switzerland)
2024

Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study.

International journal of molecular sciences
2024

New perspectives for the treatment and follow-up of glycogen storage disease type V: DL-3-hydroxybutyric acid with modified Atkins diet and quadriceps femoris shear wave elastography.

Journal of pediatric endocrinology & metabolism : JPEM
2024

Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.

Molecular genetics & genomic medicine
2024

Cardiac comorbidities in McArdle disease: case report and systematic review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

A Phosphaturic Mesenchymal Tumor Presenting as Reversible Metabolic Myopathy.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
2024

[McArdle's disease revealed by acute low back pain].

La Revue de medecine interne
2024

Evaluation of Neuromuscular Diseases and Complaints by Quantitative Muscle MRI.

Journal of clinical medicine
2024

The utility of electrodiagnostic testing in unprovoked rhabdomyolysis in the era of next-generation sequencing.

Muscle & nerve
2024

Case report: A novel ACTA1 variant in a patient with nemaline rods and increased glycogen deposition.

Frontiers in neurology
2024

Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease.

European journal of neurology
2024

Toward an Understanding of GSD5 (McArdle disease): How Do Individuals Learn to Live with the Metabolic Defect in Daily Life.

Journal of neuromuscular diseases
2024

The impact of COVID-19 infection, the pandemic and its associated control measures on patients with Pompe disease.

Journal of neurology
2023

Late-Onset Pompe Disease with Normal Creatine Kinase Levels: The Importance of Rheumatological Suspicion.

International journal of molecular sciences
2024

Experience with carnitine palmitoyltransferase II deficiency: diagnostic challenges in the myopathic form.

Journal of pediatric endocrinology & metabolism : JPEM
2023

Clinical and Laboratory Findings on Glycogen Storage Disease Type V: Results from a Retrospective Observational Study in a Tertiary Hospital.

Endocrine, metabolic & immune disorders drug targets
2023

GAA variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing.

Molecular genetics and metabolism reports
2023

Α rare case of myopathy, lactic acidosis, and severe rhabdomyolysis, due to a homozygous mutation of the ferredoxin-2 (FDX2) gene.

American journal of medical genetics. Part A
2023

NGS-Based Genetic Analysis in a Cohort of Italian Patients with Suspected Inherited Myopathies and/or HyperCKemia.

Genes
2023

Development of Continuum of Care for McArdle disease: A practical tool for clinicians and patients.

Neuromuscular disorders : NMD
2023

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
2023

[Rhabdomyolysis of rare etiology].

Innere Medizin (Heidelberg, Germany)
2023

Diagnosis and management of metabolic myopathies.

Muscle & nerve
2023

Speech Disorders in Children With Pompe Disease: Articulation, Resonance, and Voice Measures.

American journal of speech-language pathology
2023

Diagnostic Challenges of Neuromuscular Disorders after Whole Exome Sequencing.

Journal of neuromuscular diseases
2023

Primary mitochondrial disease as a rare cause of unclear breathlessness and distinctive performance degradation - a case report.

BMC pulmonary medicine
2023

Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease.

Journal of inherited metabolic disease
2023

Skeletal Muscle Bioenergetics in Critical Limb Ischemia and Diabetes.

The Journal of surgical research
2023

Anaesthetic implications for Pompe disease. A case description.

Revista espanola de anestesiologia y reanimacion
2023

High diagnostic yield of targeted next-generation sequencing panel as a first-tier molecular test for the patients with myopathy or muscular dystrophy.

Annals of human genetics
2022

Infantile-onset Pompe disease in seven Mexican children.

Gaceta medica de Mexico
2022

Secondary myoadenylate deaminase deficiency is not a common feature of inflammatory myopathies: A descriptive study.

Frontiers in medicine
2023

Diffusion tensor imaging of the brain in Pompe disease.

Journal of neurology
2023

Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment.

Endocrinology, diabetes & metabolism
2022

Anoctamin 5 (ANO5) Muscle Disorders: A Narrative Review.

Genes
2023

Safety of COVID-19 vaccines in children with inborn errors of metabolism in terms of developing metabolic decompensation.

Journal of paediatrics and child health
2023

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism.

Journal of inherited metabolic disease
2022

A genetic basis is identified in 74% cases of paediatric hyperCKaemia without weakness presenting to a tertiary paediatric neuromuscular centre.

Neuromuscular disorders : NMD
2022

[Late onset Pompe disease: an analysis of 19 patients from Mexico].

Revista de neurologia
2022

Crohn's Disease Presenting as Metabolic Myopathy: A Case Report.

Neurology India
2022

A new phenotype of muscle glycogen synthase deficiency (GSD0B) characterized by an adult onset myopathy without cardiomyopathy.

Neuromuscular disorders : NMD
2022

Identification of Potential Muscle Biomarkers in McArdle Disease: Insights from Muscle Proteome Analysis.

International journal of molecular sciences
2022

Approach to the diagnosis of metabolic myopathies.

Indian journal of pathology & microbiology
2022

Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease).

Frontiers in neurology
2022

Statin-associated immune-mediated necrotizing myositis in Native Americans.

Rheumatology (Oxford, England)
2022

Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.

European journal of translational myology
2022

Lipid-storage myopathy with glycogen storage disease gene mutations mimicking polymyositis: a case report and review of the literature.

The Journal of international medical research
2022

Skeletal muscle MiR-210 expression is associated with mitochondrial function in peripheral artery disease patients.

Translational research : the journal of laboratory and clinical medicine
2022

Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up.

Frontiers in cell and developmental biology
2022

Mild disease course of SARS-CoV-2 infections and mild side effects of vaccination in Pompe disease: a cohort description.

Orphanet journal of rare diseases
2022

No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical cross-over trial.

Journal of inherited metabolic disease
2021

A Quantitative Proteomics Approach to Gain Insight into NRF2-KEAP1 Skeletal Muscle System and Its Cysteine Redox Regulation.

Genes
2021

Energy metabolism during exercise in patients with β-enolase deficiency (GSDXIII).

JIMD reports
2021

Experience with the Urinary Tetrasaccharide Metabolite for Pompe Disease in the Diagnostic Laboratory.

Metabolites
2021

Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy.

Molecular genetics and metabolism
2021

Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease-an MRI study.

PeerJ
2021

Diagnostic yield of muscle biopsy in infants: Retrospective analysis of clinical and histopathologic findings.

Clinical neuropathology
2021

SARS-CoV-2 may unravel metabolic myopathy mistaken for myasthenia.

Revista espanola de geriatria y gerontologia
2021

A systematic review of late-onset and very-late-onset multiple acyl-coenzyme A dehydrogenase deficiency: Cohort analysis and patient report from Taiwan.

Neuromuscular disorders : NMD
2021

Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience.

Neuromuscular disorders : NMD
2021

Acute Renal Failure Secondary to an Unusual Familial Metabolic Myopathy.

Nephron
2020

Genetic cause of heterogeneous inherited myopathies in a cohort of Greek patients.

Molecular genetics and metabolism reports
2020

Very-Long-Chain Acyl-Co-Enzyme A Dehydrogenase Deficiency Presenting as Rhabdomyolysis: First Case Report from Sri Lanka.

Case reports in genetics
2020

Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy.

Journal of the American Heart Association
2020

Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.

Orphanet journal of rare diseases
2021

Cellular prion protein dysfunction in a prototypical inherited metabolic myopathy.

Cellular and molecular life sciences : CMLS
2020

A Family With a Complex Phenotype Caused by Two Different Rare Metabolic Disorders: GLUT1 and Very-Long-Chain Fatty Acid Dehydrogenase (VLCAD) Deficiencies.

Frontiers in neurology
2020

Adult-onset very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD).

European journal of neurology
2020

Lipin-1 Deficiency-Associated Recurrent Rhabdomyolysis and Exercise-Induced Myalgia Persisting into Adulthood: A Case Report and Review of Literature.

Case reports in medicine
2020

The ratio of maximal handgrip force and maximal cycloergometry power as a diagnostic tool to screen for metabolic myopathies.

Scientific reports
2020

Impaired lipolysis in propionic acidemia: A new metabolic myopathy?

JIMD reports
2020

Variants in HNRNPDL and SETX Not Necessarily Indicate Familial Amyotrophic Lateral Sclerosis or Limb Girdle Muscular Dystrophy 1G in Acute Muscular Respiratory Failure.

Journal of neurosciences in rural practice
2020

Update Review about Metabolic Myopathies.

Life (Basel, Switzerland)
2020

Neutral lipid storage disease with myopathy presenting asymmetrical muscle weakness: a case report.

International journal of clinical and experimental pathology
2020

MEHP interferes with mitochondrial functions and homeostasis in skeletal muscle cells.

Bioscience reports
2020

Fever, Fasting, and Rhabdomyolysis in an Adult Male.

Neurology India
2020

Mitochondrial Structure and Function in the Metabolic Myopathy Accompanying Patients with Critical Limb Ischemia.

Cells
2020

Diagnosis and Care of Infants and Children with Pompe Disease.

Klinische Padiatrie
2020

Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families.

Journal of pediatric endocrinology & metabolism : JPEM
2019

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.

Journal of clinical medicine
2020

Absence of p.R50X Pygm read-through in McArdle disease cellular models.

Disease models & mechanisms
2019

[Follow-up study in German Hunting Terrier dogs with exercise induced metabolic myopathy].

Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
2019

McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.

International journal of molecular sciences
2019

The need for biochemical testing in beta-enolase deficiency in the genomic era.

JIMD reports
2020

Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy.

Mitochondrion
2019

Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.

Annals of translational medicine
2019

Late-onset Pompe disease manifests in the brain.

Molecular genetics and metabolism reports
2019

Early-age Ndufs4 knockout mice are an inappropriate animal model of Leigh syndrome.

Radiological physics and technology
2019

Novel Asp511Thr mutation in McArdle disease with acute kidney injury caused by rhabdomyolysis.

CEN case reports
2019

Loss of RNA-Binding Protein Sfpq Causes Long-Gene Transcriptopathy in Skeletal Muscle and Severe Muscle Mass Reduction with Metabolic Myopathy.

iScience
2019

Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2019

HADHA and HADHB gene associated phenotypes - Identification of rare variants in a patient cohort by Next Generation Sequencing.

Molecular and cellular probes
2019

Phenotypic expression of POLG1 variants is highly heterogeneous.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2019

A Hemizygous Deletion Within the PGK1 Gene in Males with PGK1 Deficiency.

JIMD reports
2019

Leigh-like syndrome with mild mtDNA depletion due to the SUCLG1 variant c.626C > T.

Molecular genetics and metabolism reports
2019

Total thyroidectomys in patient with McArdle's syndrome: Anesthetic management.

Revista espanola de anestesiologia y reanimacion
2020

Single-centre experience on genotypic and phenotypic features of southern Brazilian patients with McArdle disease.

Acta neurologica Belgica
2018

Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.

Acta neuropathologica communications
2018

Follow-up analysis of voice quality in patients with late-onset Pompe disease.

Orphanet journal of rare diseases
2018

Resistance Exercise Training in McArdle Disease: Myth or Reality?

Case reports in neurological medicine
2018

Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study.

Orphanet journal of rare diseases
2018

Dilative arteriopathy in Pompe disease may not only affect the cerebral arteries.

Molecular genetics and metabolism reports
2018

Carnitine palmitoyltransferase type 2 deficiency: novel mutation in a Native South American family with whole-body muscle magnetic resonance imaging findings: two case reports.

Journal of medical case reports
2018

Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.

International journal of cardiology
2018

A new AMPK activator, GSK773, corrects fatty acid oxidation and differentiation defect in CPT2-deficient myotubes.

Human molecular genetics
2018

FDG PET/CT of Metabolic Myopathy With Posttreatment Follow-up.

Clinical nuclear medicine
2018

Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.

Neuromuscular disorders : NMD
2018

Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.

Neurologia i neurochirurgia polska
2018

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.

Orphanet journal of rare diseases
2018

Oxidative stress and antioxidant treatment in patients with peripheral artery disease.

Physiological reports
2018

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.

Journal of inherited metabolic disease
2018

Patients with neutral lipid storage disease with myopathy (NLSDM) in Southwestern China.

Clinical neurology and neurosurgery
2018

A Nonsense Variant in the ACADVL Gene in German Hunting Terriers with Exercise Induced Metabolic Myopathy.

G3 (Bethesda, Md.)
2018

Wave of renal impairment.

BMJ case reports
2018

Metabolic myopathies: a practical approach.

Practical neurology
2017

[Rhabdomyolysis - may it be a metabolic myopathy? Case report and diagnostic algorithm].

Orvosi hetilap
2017

Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Molecular genetics and metabolism
2017

AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease.

Scientific reports
2017

De novo Mutation in CACNA1S Gene in a 20-Year-Old Man Diagnosed with Metabolic Myopathy.

Archives of Iranian medicine
2017

Fatty acid oxidation defects presenting as primary myopathy and prominent dropped head syndrome.

Neuromuscular disorders : NMD
2017

Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa.

Molecular genetics and metabolism
2017

Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency.

Molecular genetics and metabolism
2017

Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.

Journal of neuropathology and experimental neurology
2018

Screening for late-onset Pompe disease in western Denmark.

Acta neurologica Scandinavica
2017

Three cases of multi-generational Pompe disease: Are current practices missing diagnostic and treatment opportunities?

American journal of medical genetics. Part A
2017

Psoriasis, bulbar involvement, and diarrhea in late myoclonic epilepsy with ragged-red fibers-syndrome due to the m.8344A > G tRNA (Lys) mutation.

Iranian journal of neurology
2017

GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells.

Molecular therapy. Nucleic acids
2017

Multisystem Disease, Including Eosinophilia and Progressive Hyper-Creatine-Kinase-emia over 10 Years, Suggests Mitochondrial Disorder.

Case reports in neurology
2017

Skeletal muscle metabolism during prolonged exercise in Pompe disease.

Endocrine connections
2018

Mutations in GMPPB Presenting with Pseudometabolic Myopathy.

JIMD reports
2017

Mitochondrial Bioenergetics in the Metabolic Myopathy Accompanying Peripheral Artery Disease.

Frontiers in physiology
2017

Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy.

Journal of neuromuscular diseases
2017

Clinical Analysis of Algerian Patients with Pompe Disease.

Journal of neurodegenerative diseases
2016

Adult-onset Pompe's disease presenting with insidious hypercapnic respiratory failure.

Respirology case reports
2017

Muscle fiber type proportion and size is not altered in mcardle disease.

Muscle & nerve
2016

Clinical, histopathological and metabolic responses following exercise in Arabian horses with a history of exertional rhabdomyolysis.

Veterinary journal (London, England : 1997)
2016

Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.

Neuromuscular disorders : NMD
2017

Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders.

Journal of medical genetics
2016

Malingering and Factitious Disorder (Münchausen-syndrome) can be Mitochondrial.

Indian journal of psychological medicine
2016

Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III.

Neuromuscular disorders : NMD
2016

Analysis of voice quality in patients with late-onset Pompe disease.

Orphanet journal of rare diseases
2016

Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI.

PloS one
2015

A multi-parametric protocol to study exercise intolerance in McArdle's disease.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2016

Anesthetic management of 877 pediatric patients undergoing muscle biopsy for neuromuscular disorders: a 20-year review.

Paediatric anaesthesia
2016

Metabolic myopathy facilitating the development of Takotsubo syndrome.

International journal of cardiology
2016

Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.

Clinical rheumatology
2015

Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.

Molecular genetics and metabolism reports
2016

Primary hyperparathyroidism: A changing scenario in India.

Indian journal of endocrinology and metabolism
2016

Recurrent episodes of myoglobinuria, mental retardation and seizures but no hemolysis in two brothers with phosphoglycerate kinase deficiency.

Neuromuscular disorders : NMD
2016

Oncocytoma and noncompaction in metabolic myopathy.

International journal of cardiology
2015

[Application of targeted capture technology and next generation sequencing in molecular diagnosis of inherited myopathy].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2015

Pompe disease: Shared and unshared features of lysosomal storage disorders.

Rare diseases (Austin, Tex.)
2016

Reverse fiber type disproportion: A distinct metabolic myopathy.

Muscle & nerve
2015

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease.

Acta neuropathologica communications
2016

[Telephone enquiries on the topic of malignant hyperthermia: Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig].

Der Anaesthesist
2015

Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned.

JAMA neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Miopatia metabólica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Miopatia metabólica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.
    Neurology. Clinical practice· 2026· PMID 41726791mais citado
  2. Myopathy and ataxia related to impaired mitochondrial function in mevalonate kinase deficiency.
    Orphanet journal of rare diseases· 2026· PMID 41680896mais citado
  3. EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia.
    European journal of neurology· 2026· PMID 41619221mais citado
  4. Loss of adenylosuccinate synthetase 1 in mice recapitulates features of ADSS1 myopathy.
    Human molecular genetics· 2026· PMID 41263703mais citado
  5. The Impact of Muscle Fatigue on McArdle Disease: A Case Report.
    Cureus· 2026· PMID 41835783mais citado
  6. Pediatric HyperCKemia: a 13-year retrospective study and predictors of neuromuscular disease and metabolic myopathy.
    Eur J Pediatr· 2026· PMID 41961319recente
  7. Fibre morphology, intramyocellular lipid content and 3D capillary architecture in human postural, respiratory and locomotor muscles in type 2 diabetes mellitus.
    Histochem Cell Biol· 2026· PMID 41941000recente
  8. Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1-Mediated AMPK Signalling.
    J Cachexia Sarcopenia Muscle· 2026· PMID 41922933recente
  9. Mapping lung function in late-onset Pompe disease using label-free functional MRI.
    iScience· 2026· PMID 41883578recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98486(Orphanet)
  2. MONDO:0020123(MONDO)
  3. GARD:19472(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q6822345(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Miopatia metabólica
Compêndio · Raras BR

Miopatia metabólica

ORPHA:98486 · MONDO:0020123
MedGen
UMLS
C0270984
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades